159 related articles for article (PubMed ID: 21048313)
1. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity.
Katsuda H; Yamashita M; Katsura H; Yu J; Waki Y; Nagata N; Sai Y; Miyamoto K
Biol Pharm Bull; 2010; 33(11):1867-71. PubMed ID: 21048313
[TBL] [Abstract][Full Text] [Related]
2. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance.
Sprowl JA; van Doorn L; Hu S; van Gerven L; de Bruijn P; Li L; Gibson AA; Mathijssen RH; Sparreboom A
Clin Pharmacol Ther; 2013 Nov; 94(5):585-92. PubMed ID: 23863876
[TBL] [Abstract][Full Text] [Related]
3. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
Fox E; Levin K; Zhu Y; Segers B; Balamuth N; Womer R; Bagatell R; Balis F
Oncologist; 2018 Jul; 23(7):762-e79. PubMed ID: 29445029
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.
Tanihara Y; Masuda S; Katsura T; Inui K
Biochem Pharmacol; 2009 Nov; 78(9):1263-71. PubMed ID: 19540211
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport.
Ludwig T; Riethmüller C; Gekle M; Schwerdt G; Oberleithner H
Kidney Int; 2004 Jul; 66(1):196-202. PubMed ID: 15200426
[TBL] [Abstract][Full Text] [Related]
6. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.
Franke RM; Kosloske AM; Lancaster CS; Filipski KK; Hu C; Zolk O; Mathijssen RH; Sparreboom A
Clin Cancer Res; 2010 Aug; 16(16):4198-206. PubMed ID: 20601443
[TBL] [Abstract][Full Text] [Related]
7. Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients.
Zhang J; Zhou W
Food Chem Toxicol; 2012 Jul; 50(7):2289-93. PubMed ID: 22525860
[TBL] [Abstract][Full Text] [Related]
8. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.
Ciarimboli G; Deuster D; Knief A; Sperling M; Holtkamp M; Edemir B; Pavenstädt H; Lanvers-Kaminsky C; am Zehnhoff-Dinnesen A; Schinkel AH; Koepsell H; Jürgens H; Schlatter E
Am J Pathol; 2010 Mar; 176(3):1169-80. PubMed ID: 20110413
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine improves renal hemodynamics in rats with cisplatin-induced nephrotoxicity.
Abdelrahman AM; Al Salam S; AlMahruqi AS; Al husseni IS; Mansour MA; Ali BH
J Appl Toxicol; 2010 Jan; 30(1):15-21. PubMed ID: 19681060
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin.
Mody H; Vaidya TR; Lesko LJ; Ait-Oudhia S
Cells; 2022 Dec; 12(1):. PubMed ID: 36611850
[TBL] [Abstract][Full Text] [Related]
11. L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy.
Li C; Li L; Yi Y; Wang W; Yuan J; Tan F; Fang D; Zeng S; Zhou H; Jiang H
Biochem Pharmacol; 2020 Jul; 177():114021. PubMed ID: 32389634
[TBL] [Abstract][Full Text] [Related]
12. Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats.
Hiramatsu SI; Ikemura K; Fujisawa Y; Iwamoto T; Okuda M
Biopharm Drug Dispos; 2020 Jun; 41(6):239-247. PubMed ID: 32473602
[TBL] [Abstract][Full Text] [Related]
13. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.
Yokoo S; Yonezawa A; Masuda S; Fukatsu A; Katsura T; Inui K
Biochem Pharmacol; 2007 Aug; 74(3):477-87. PubMed ID: 17582384
[TBL] [Abstract][Full Text] [Related]
14. [Platinum agent-induced nephrotoxicity via organic cation transport system].
Yonezawa A
Yakugaku Zasshi; 2012; 132(11):1281-5. PubMed ID: 23123720
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.
Robl B; Botter SM; Pellegrini G; Neklyudova O; Fuchs B
J Exp Clin Cancer Res; 2016 Jul; 35(1):113. PubMed ID: 27421768
[TBL] [Abstract][Full Text] [Related]
16. Nephroprotective efficacy of chrysin against cisplatin-induced toxicity via attenuation of oxidative stress.
Sultana S; Verma K; Khan R
J Pharm Pharmacol; 2012 Jun; 64(6):872-81. PubMed ID: 22571266
[TBL] [Abstract][Full Text] [Related]
17. Sex and age differences related to renal OCT2 gene expression in cisplatin-induced nephrotoxicity.
El-Arabey AA
Iran J Kidney Dis; 2015 Jul; 9(4):335-6. PubMed ID: 26174463
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
19. Shikonin induces apoptosis through reactive oxygen species/extracellular signal-regulated kinase pathway in osteosarcoma cells.
Chang IC; Huang YJ; Chiang TI; Yeh CW; Hsu LS
Biol Pharm Bull; 2010; 33(5):816-24. PubMed ID: 20460760
[TBL] [Abstract][Full Text] [Related]
20. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
